GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hisamitsu Pharmaceutical Co Inc (TSE:4530) » Definitions » Debt-to-EBITDA

Hisamitsu Pharmaceutical Co (TSE:4530) Debt-to-EBITDA : 0.06 (As of Nov. 2023)


View and export this data going back to 1962. Start your Free Trial

What is Hisamitsu Pharmaceutical Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Hisamitsu Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2023 was 円1,071 Mil. Hisamitsu Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2023 was 円95 Mil. Hisamitsu Pharmaceutical Co's annualized EBITDA for the quarter that ended in Nov. 2023 was 円20,104 Mil. Hisamitsu Pharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in Nov. 2023 was 0.06.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Hisamitsu Pharmaceutical Co's Debt-to-EBITDA or its related term are showing as below:

TSE:4530' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.06   Med: 0.07   Max: 0.14
Current: 0.11

During the past 13 years, the highest Debt-to-EBITDA Ratio of Hisamitsu Pharmaceutical Co was 0.14. The lowest was 0.06. And the median was 0.07.

TSE:4530's Debt-to-EBITDA is ranked better than
86.97% of 660 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs TSE:4530: 0.11

Hisamitsu Pharmaceutical Co Debt-to-EBITDA Historical Data

The historical data trend for Hisamitsu Pharmaceutical Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hisamitsu Pharmaceutical Co Debt-to-EBITDA Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.10 0.14 0.11 0.09

Hisamitsu Pharmaceutical Co Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.05 0.05 0.06 0.21

Competitive Comparison of Hisamitsu Pharmaceutical Co's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hisamitsu Pharmaceutical Co's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Hisamitsu Pharmaceutical Co's Debt-to-EBITDA falls into.



Hisamitsu Pharmaceutical Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Hisamitsu Pharmaceutical Co's Debt-to-EBITDA for the fiscal year that ended in Feb. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1421 + 679) / 24376
=0.09

Hisamitsu Pharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in Nov. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1071 + 95) / 20104
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Nov. 2023) EBITDA data.


Hisamitsu Pharmaceutical Co  (TSE:4530) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Hisamitsu Pharmaceutical Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Hisamitsu Pharmaceutical Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Hisamitsu Pharmaceutical Co (TSE:4530) Business Description

Traded in Other Exchanges
Address
408 Tashiro Daikan-machi, Tosu, Saga, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is a major pharmaceutical products manufacturer in Japan. The company collaborates with its subsidiaries and associates in operating its business across two segments, The Medical and Related Product segment and the Others segment. The Medical segment represents the company's foremost revenue generating operations. It markets drugs under the Salanpas, Salonsip, Lifecella, Mohrus and Keplat brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions and ointments. The Others segment refers to its miscellaneous businesses such as cable television broadcasting, internet connection, packing materials and insurance. Apart from its primary market in Japan, Hisamitsu has a reach across other regions like North America.

Hisamitsu Pharmaceutical Co (TSE:4530) Headlines

No Headlines